BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 1560924)

  • 1. Treatment of extensively invasive (giant) prolactinomas with bromocriptine.
    Grebe SK; Delahunt JW; Feek CM
    N Z Med J; 1992 Apr; 105(931):129-31. PubMed ID: 1560924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Giant invasive prolactinoma: a case report and review of nine further cases.
    Davis JR; Sheppard MC; Heath DA
    Q J Med; 1990 Mar; 74(275):227-38. PubMed ID: 2385731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance.
    Delgrange E; Sassolas G; Perrin G; Jan M; Trouillas J
    Acta Neurochir (Wien); 2005 Jul; 147(7):751-7; discussion 757-8. PubMed ID: 15971099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Bromocriptine treatment of invasive giant prolactinomas prior to comprehensive treatments: results of a long-term follow up].
    Zhang HW; Yu CJ; Sun W; Yang J; Yan CX; Cun EH
    Zhonghua Wai Ke Za Zhi; 2006 Nov; 44(22):1555-7. PubMed ID: 17359664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Invasive giant prolactinoma].
    Domínguez Ugidos LJ; Martínez Subías J; Urpegui García A; Sancho Serrano E; Alfonso Collado JI; Vallés Varela H
    Acta Otorrinolaringol Esp; 1998 Mar; 49(2):156-8. PubMed ID: 9650316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of prolactinoma with a new dopamine agonist].
    Svoboda T; Luger A; Knosp E; Geyer G
    Dtsch Med Wochenschr; 1991 Aug; 116(33):1224-7. PubMed ID: 1678695
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Giant prolactinomas: clinical management and long-term follow up.
    Shrivastava RK; Arginteanu MS; King WA; Post KD
    J Neurosurg; 2002 Aug; 97(2):299-306. PubMed ID: 12186457
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine function, psychiatric and clinical consequences in patients with macroprolactinomas after long-term treatment with the new non-ergot dopamine agonist CV205-502.
    Barnett PS; Palazidou E; Miell JP; Coskeran PB; Butler J; Dawson JM; Maccabe J; McGregor AM
    Q J Med; 1991 Nov; 81(295):891-906. PubMed ID: 1687293
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Results of treatment for male prolactinomas].
    Iwai Y; Yamanaka K; Ishiguro T; Morikawa T; Matsuzaka Y; Komiyama M; Yasui T
    No Shinkei Geka; 2002 Dec; 30(12):1285-92. PubMed ID: 12491580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up.
    Wu ZB; Yu CJ; Su ZP; Zhuge QC; Wu JS; Zheng WM
    J Neurosurg; 2006 Jan; 104(1):54-61. PubMed ID: 16509147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
    Glaser B; Nesher Y; Barziliai S
    J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment strategy of pituitary invasive prolactinomas].
    Wu ZB; Yu CJ
    Zhonghua Wai Ke Za Zhi; 2009 Jan; 47(2):123-7. PubMed ID: 19563008
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion.
    Wu ZB; Su ZP; Wu JS; Zheng WM; Zhuge QC; Zhong M
    Pituitary; 2008; 11(1):63-70. PubMed ID: 17917811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of surgery for the treatment of prolactinomas.
    van't Verlaat JW
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():34-7. PubMed ID: 8103958
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medical therapy of prolactinomas.
    Jaquet P
    Acta Endocrinol (Copenh); 1993 Jul; 129 Suppl 1():31-3. PubMed ID: 8103957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cabergoline for the treatment of bromocriptine-resistant invasive giant prolactinomas.
    Huang HY; Zhai W; Tang H; Hui GZ; Wu ZB
    Endocrine; 2018 Nov; 62(2):464-469. PubMed ID: 30238326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-surgical management of cystic prolactinomas.
    Bahuleyan B; Menon G; Nair S; Rao BR; Easwer HV; Krishna K
    J Clin Neurosci; 2009 Nov; 16(11):1421-4. PubMed ID: 19699096
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Effects of therapy and pregnancy on hyperprolactemia caused by a pituitary adenoma. A clinical case].
    Pasinetti E; Schivardi MR; Falsetti L; Gastaldi A
    Minerva Ginecol; 1989 Mar; 41(3):157-60. PubMed ID: 2666885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The treatment of prolactinoma].
    Serri O; Somma M; Beauregard H; Rasio E; Comtois R; Aris-Jilwan N; Boucher A; Hardy J
    Union Med Can; 1993; 122(6):496-9. PubMed ID: 7905686
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined treatment of invasive giant prolactinomas.
    Yu C; Wu Z; Gong J
    Pituitary; 2005; 8(1):61-5. PubMed ID: 16411070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.